Reuven Zev Cohen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Reuven Zev Cohen has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
A. Jay Freeman
Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Emory University School of Medicine, Children’s Healthcare of Atlanta, 1400 Tullie Road Northeast, Atlanta, GA 30329, USA
2 shared publicationsCary G. Sauer
Division of Pediatric Gastroenterology, Hepatology, and Nutrition Emory University School of Medicine Children's Healthcare of Atlanta Atlanta GA
2 shared publications- Aliye Uc
Stead Family Department of Pediatrics, University of Iowa, Iowa City, IA 52242, U.S.A.
1 shared publication - Alvin Jay Freeman
Division of Pediatric Gastroenterology, Hepatology and Nutrition Nationwide Children's Hospital Columbus Ohio USA
1 shared publication Amit S. Grover
Boston Children's, United States
1 shared publicationAndrew B. Muir
1 shared publication
Latest Publications
- 2 February 2026
- Published by Elsevier in Pancreatology
- Vol. 26 (4) , 525-531
Long-term disease progression in pediatric acute recurrent and chronic pancreatitis: A report from INSPPIRE
- 2 February 2026
- Published by Elsevier in Pancreatology
- Vol. 26 (4) , 525-531
Long-term disease progression in pediatric acute recurrent and chronic pancreatitis: A report from INSPPIRE
- 2 November 2021
- Published by Elsevier in Pediatric Clinics of North America
- Vol. 68 (6) , 1273-1291
Pancreatitis in Children
- 2 November 2021
- Published by Elsevier in Pediatric Clinics of North America
- Vol. 68 (6) , 1273-1291
Pancreatitis in Children
- 29 June 2021
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 73 (5) , 636-641
Creation of a Pediatric Choledocholithiasis Prediction Model
Background: Definitive non‐invasive detection of pediatric choledocholithiasis could allow more efficient identification of those patients who are most likely to benefit from therapeutic endoscopic retrograde cholangiopancreatography (ERCP) for stone extraction.Objective: To craft a pediatric choledocholithiasis prediction model using a combination of commonly available serum laboratory values and ultrasound results.Methods: A retrospective review of laboratory and imaging results from 316 pediatric patients who underwent intraoperative cholangiogram or ERCP due to suspicion of choledocholithiasis were collected and compared to presence of common bile duct stones on cholangiography. Multivariate logistic regression with supervised machine learning was used to create a predictive scoring model. Monte‐Carlo cross‐validation was used to validate the scoring model and a score threshold that would provide at least 90% specificity for choledocholithiasis was determined in an effort to minimize non‐therapeutic ERCP.Results: Alanine aminotransferase (ALT), total bilirubin, alkaline phosphatase, and common bile duct diameter via ultrasound were found to be the key clinical variables to determine the likelihood of choledocholithiasis. The dictated specificity threshold of 90.3% yielded a sensitivity of 40.8% and overall accuracy of 71.5% in detecting choledocholithiasis. Positive predictive value was 71.4% and negative predictive value was 72.1%.Conclusion: Our novel pediatric choledocholithiasis predictive model is a highly specific tool to suggest ERCP in the setting of likely choledocholithiasis.
- 29 June 2021
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 73 (5) , 636-641
Creation of a Pediatric Choledocholithiasis Prediction Model
Background: Definitive non‐invasive detection of pediatric choledocholithiasis could allow more efficient identification of those patients who are most likely to benefit from therapeutic endoscopic retrograde cholangiopancreatography (ERCP) for stone extraction.Objective: To craft a pediatric choledocholithiasis prediction model using a combination of commonly available serum laboratory values and ultrasound results.Methods: A retrospective review of laboratory and imaging results from 316 pediatric patients who underwent intraoperative cholangiogram or ERCP due to suspicion of choledocholithiasis were collected and compared to presence of common bile duct stones on cholangiography. Multivariate logistic regression with supervised machine learning was used to create a predictive scoring model. Monte‐Carlo cross‐validation was used to validate the scoring model and a score threshold that would provide at least 90% specificity for choledocholithiasis was determined in an effort to minimize non‐therapeutic ERCP.Results: Alanine aminotransferase (ALT), total bilirubin, alkaline phosphatase, and common bile duct diameter via ultrasound were found to be the key clinical variables to determine the likelihood of choledocholithiasis. The dictated specificity threshold of 90.3% yielded a sensitivity of 40.8% and overall accuracy of 71.5% in detecting choledocholithiasis. Positive predictive value was 71.4% and negative predictive value was 72.1%.Conclusion: Our novel pediatric choledocholithiasis predictive model is a highly specific tool to suggest ERCP in the setting of likely choledocholithiasis.
- Open Access
- 1 November 2019
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 69 (5) , 551-556
Management of Anti‐drug Antibodies to Biologic Medications in Children With Inflammatory Bowel Disease
Background: Treatment of pediatric inflammatory bowel disease (IBD) with monoclonal anti‐ tumor necrosis factor‐alpha (TNFα) can result in immunogenicity and formation of anti‐drug antibodies (ADAs). ADAs are associated with loss of clinical response and worsening disease progression. Data examining treatment interventions to overcome ADA in pediatric patients with IBD are lacking.Results: Medical records were reviewed from 234 children and adolescents with IBD treated with infliximab or adalimumab who underwent therapeutic drug monitoring (626 tests). All patients who had detectable antibodies were further analyzed. A total 58 patients (24.8%) developed ADA while being treated with infliximab or adalimumab. The incidence of antibody development was 12.9 per 100 person‐years of anti‐TNF treatment. Twenty‐eight patients underwent dose optimization and 54% had undetectable ADA on follow‐up monitoring. The mean duration of antibody suppression was 16.8 ± 10.9 months in those who were successfully suppressed with optimization. Patients who switched to a second anti‐TNF medication were not more likely to develop antibodies to the second agent.Conclusions: With limited therapies for IBD and the chronicity of the disease, we advocate salvage of the current anti‐TNF through dose optimization in pediatric patients with antibody level <10 U/mL.
- 1 November 2019
- Published by Wiley in Journal of Pediatric Gastroenterology and Nutrition
- Vol. 69 (5) , 551-556
Open AccessManagement of Anti‐drug Antibodies to Biologic Medications in Children With Inflammatory Bowel Disease
Background: Treatment of pediatric inflammatory bowel disease (IBD) with monoclonal anti‐ tumor necrosis factor‐alpha (TNFα) can result in immunogenicity and formation of anti‐drug antibodies (ADAs). ADAs are associated with loss of clinical response and worsening disease progression. Data examining treatment interventions to overcome ADA in pediatric patients with IBD are lacking.Results: Medical records were reviewed from 234 children and adolescents with IBD treated with infliximab or adalimumab who underwent therapeutic drug monitoring (626 tests). All patients who had detectable antibodies were further analyzed. A total 58 patients (24.8%) developed ADA while being treated with infliximab or adalimumab. The incidence of antibody development was 12.9 per 100 person‐years of anti‐TNF treatment. Twenty‐eight patients underwent dose optimization and 54% had undetectable ADA on follow‐up monitoring. The mean duration of antibody suppression was 16.8 ± 10.9 months in those who were successfully suppressed with optimization. Patients who switched to a second anti‐TNF medication were not more likely to develop antibodies to the second agent.Conclusions: With limited therapies for IBD and the chronicity of the disease, we advocate salvage of the current anti‐TNF through dose optimization in pediatric patients with antibody level <10 U/mL.
- 1 January 2016
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 29 (3) , 319-25
Outcomes analysis of radioactive iodine and total thyroidectomy for pediatric Graves’ disease
The majority of pediatric patients with Graves’ disease will ultimately require definitive therapy in the form of radioactive iodine (RAI) ablation or thyroidectomy. There are few studies that directly compare the efficacy and complication rates between RAI and thyroidectomy. We compared the relapse rate as well as the acute and long-term complications of RAI and total thyroidectomy among children and adolescents with Graves’ disease treated at our center.Medical records from 81 children and adolescents with a diagnosis of Graves’ disease who received definitive therapy over a 12-year period were reviewed.Fifty one patients received RAI and 30 patients underwent thyroidectomy. The relapse rate was not significantly different between RAI and thyroidectomy (12.1% vs. 0.0%, p=0.28). There were no acute or long-term complications in the RAI group, but there were eight cases of hypoparathyroidism (two transient and six permanent) in the thyroidectomy group. None of the patients developed a recurrent laryngeal nerve injury.RAI is a safe and effective option for treatment of children and adolescents with Graves’ disease. In light of the rate of permanent hypoparathyroidism seen at our center with thyroidectomy and previously published long-term safety of RAI, we recommend RAI as the first line treatment for children and adolescents with Graves’ disease. For those centers performing thyroidectomies, we recommend that each center select 1–2 high-volume pediatric surgeons to perform all thyroid procedures, allowing individuals to increases case volume and potentially decrease long-term complications of thyroidectomy.
- 1 January 2016
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 29 (3) , 319-25
Outcomes analysis of radioactive iodine and total thyroidectomy for pediatric Graves’ disease
The majority of pediatric patients with Graves’ disease will ultimately require definitive therapy in the form of radioactive iodine (RAI) ablation or thyroidectomy. There are few studies that directly compare the efficacy and complication rates between RAI and thyroidectomy. We compared the relapse rate as well as the acute and long-term complications of RAI and total thyroidectomy among children and adolescents with Graves’ disease treated at our center.Medical records from 81 children and adolescents with a diagnosis of Graves’ disease who received definitive therapy over a 12-year period were reviewed.Fifty one patients received RAI and 30 patients underwent thyroidectomy. The relapse rate was not significantly different between RAI and thyroidectomy (12.1% vs. 0.0%, p=0.28). There were no acute or long-term complications in the RAI group, but there were eight cases of hypoparathyroidism (two transient and six permanent) in the thyroidectomy group. None of the patients developed a recurrent laryngeal nerve injury.RAI is a safe and effective option for treatment of children and adolescents with Graves’ disease. In light of the rate of permanent hypoparathyroidism seen at our center with thyroidectomy and previously published long-term safety of RAI, we recommend RAI as the first line treatment for children and adolescents with Graves’ disease. For those centers performing thyroidectomies, we recommend that each center select 1–2 high-volume pediatric surgeons to perform all thyroid procedures, allowing individuals to increases case volume and potentially decrease long-term complications of thyroidectomy.